phone +1 (647) 3757 499 email contact@exceleve.com

EIRD 2021

A Global Debate on Infectious Diseases: R&D, Therapeutics and Management

Home / Submission & Sessions

Call for Abstracts

  1. Coronavirus (COVID 19)
  2. Novel Trends in Emerging Diseases Management
  3. Perioperative considerations for patients with COVID-19
  4. CDC recommendations on face covers in the context of COVID-19
  5. Future Epidemics: Prediction, Control and Prevention
  6. Remdesivir in COVID-19
  7. COVID-19 and Pregnancy
  8. Coronavirus 2019 (COVID-19) Pandemic
  9. COVID-19 and Ischemic Stroke
  10. Investigational approaches for COVID-19 therapy
  11. Clinical features of COVID-19 in children
  12. Management of the intubated COVID-19 patient
  13. Modification of existing antimicrobials to overcome emergent resistance
  14. Clinical Trials and Global Update on Vaccines
  15. What's new in Infectious and Unprecedented diseases
  16. Epidemiology and Infection
  17. Epidemiology and Community Health
  18. Epidemiology and Disease Control, Trends in Maternal Mortality
  19. Primary care epidemiology, Paediatric epidemiology
  20. FLU and Future Epidemic and Pandemic Diseases
  21. Adaptive Immunity and Herd Immunity
  22. Neurologic complications of severe COVID-19
  23. BioEthics and Clinical Trials and Alternative Approaches
  24. COVID 19 and Phylogenetic analysis
  25. Therapeutic Strategies
  26. Transmission Prevention Strategies and Basic Methods
  27. Bacillus anthracis (anthrax)
  28. Balamuthia mandrillaris (new in FY14)
  29. Bartonella henselae
  30. BK virus (new in FY14)
  31. Bordetella pertussis (new in FY15)
  32. Borrelia mayonii (new in FY18)
  33. Borrelia miyamotoi (new in FY14)
  34. Brucella species (brucellosis)
  35. Bunyaviruses
  36. Burkholderia mallei (glanders)
  37. Burkholderia mallei (glanders)
  38. Burkholderia pseudomallei (melioidosis)
  39. Caliciviruses
  40. California encephalitis
  41. Campylobacter jejuni
  42. Category C Priority Pathogens
  43. Chikungunya Virus
  44. Chlamydia psittaci (Psittacosis)
  45. Clostridium botulinum toxin (botulism)
  46. Coccidioides spp.
  47. Coxiella burnetii (Q fever)
  48. Cryptosporidium parvum
  49. Cyclospora cayatanensis
  50. Dengue
  51. Diarrheagenic E.coli
  52. Eastern equine encephalitis (EEE)
  53. Ehrlichiosis
  54. Entamoeba histolytica
  55. Enterovirus 68 (new in FY15)
  56. Enterovirus 71
  57. Epsilon toxin (Clostridium perfringens)
  58. European subtype
  59. Far Eastern subtype
  60. Food- and waterborne pathogens
  61. Francisella tularensis (tularemia)
  62. Fungi
  63. Giardia lamblia
  64. Hantaviruses causing Hanta Pulmonary syndrome, Rift Valley Fever, Crimean Congo Hemorrhagic Fever
  65. Hepatitis A
  66. Hepatitis C (new in FY14)
  67. Hepatitis E (new in FY14)
  68. Human herpesvirus 6
  69. Human herpesvirus 8
  70. Immunological Studies
  71. Immunology studies that advance our understanding of host defenses applicable to the biodefense effort, for example
  72. Influenza virus
  73. Innate Immunity
  74. Japanese encephalitis virus (JE)
  75. JC virus (new in FY14)
  76. Junin, Machupo, Guanarito, Chapare (new in fiscal year (FY14), Lassa, Lujo (new in FY14)
  77. LaCrosse encephalitis (LACV)
  78. Leptospirosis (new in FY14)
  79. Listeria monocytogenes
  80. Microsporidia
  81. Mosquito-borne viruses
  82. Mucormycosis (new in FY14)
  83. Mucosal Immunity
  84. Naegleria fowleri (new in FY14)
  85. Naegleria fowleri (new in FY14)
  86. Nipah and Hendra viruses
  87. Omsk Hemorrhagic Fever virus, Alkhurma virus, Kyasanur Forest virus
  88. Other Rickettsias
  89. Pathogenic Vibrios
  90. Poliovirus (new in FY15)
  91. Powassan/Deer Tick virus
  92. Prions
  93. Protozoa
  94. Rabies virus
  95. Research on mechanisms of antimicrobial resistance
  96. Research on therapeutic approaches that target resistance mechanisms
  97. Ricin toxin (Ricinus communis)
  98. Rubeola (measles) (new in FY14)
  99. Salmonella
  100. Severe acute respiratory syndrome associated coronavirus (SARS-CoV), MERS-CoV, and other highly pathogenic human coronaviruses (new in FY14)
  101. Severe Fever with Thrombocytopenia Syndrome virus (SFTSV), Heartland virus
  102. Shigella species
  103. Siberian subtype
  104. Tuberculosis, including drug-resistant TB
  105. St. Louis encephalitis virus (SLEV)
  106. Staphylococcus enterotoxin B (SEB)
  107. Streptococcus, Group A
  108. Studies of the emergence and/or spread of antimicrobial resistance genes within pathogen populations
  109. Studies of the emergence and/or spread of antimicrobial-resistant pathogens in human populations
  110. Tickborne encephalitis complex flaviviruses
  111. Tickborne encephalitis viruses
  112. Tickborne hemorrhagic fever viruses
  113. Toxoplasma gondii
  114. Respiratory management for the nonintubated COVID-19 patient
  115. Typhus fever (Rickettsia prowazekii)
  116. Variola major (smallpox) and other related pox viruses
  117. CDC and ASN issue COVID-19 guidelines for care of patients on dialysis
  118. Venezuelan equine encephalitis (VEE)
  119. Viral hemorrhagic fevers
  120. Viruses
  121. West Nile virus (WNV)
  122. Yersinia enterocolitica
  123. Western equine encephalitis (WEE)
  124. Yellow fever virus (YFV)
  125. Yersinia pestis (plague)
  126. Zika virus

WHY ATTEND?

  • Global Updates on Infectious Diseases, Emerging Infectious Diseases, Unprecedented Outbreaks and Management
  • CE, CME & CPD Credits
  • 1 to 1 meeting set up with speaker/delegate of interest
  • Cutting edge discussions on latest advancements by experts
  • Reviewed abstracts will be published in conference souvenir with DOI
  • Presentations from the World-class Keynote Speakers and Society members
  • Career Development Sessions
  • Certificate of Accreditation from the Scientific Committee
  • Post Conference Networking
  • Brainstorming sessions for students
  • Panel Discussions by Session Chairs & Co speakers
  • All reviewed and accepted abstracts will be published in the Conference Proceedings book and in International Journals.
  • Certificate of Accreditation from the Scientific Committee